Natera, Inc. NTRA
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- +70.63%
- 1 year
- +96.50%
- Open
- 418.41
- Prev close
- 414.30
- Mkt cap
- 56.35B
- Vol
- 568.49K
- Avg vol
- 1.54M
- EPS
- -1.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 390.28
- High
- 418.41
- Forward P/E
- -2329.62
- Beta
- 1.50
- Short ratio
- 3.13
- Inst. own
- 96.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 375.27
- 200-d avg
- 265.27
- 1y target
- 416.39
5D chart
Events in this range
- Oct 27, 2026Rating: BTIG · Buy → Buy
Signals (112)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Nov 2, 10:30 AM | 25 minutes ago |
| RSI: Oversold | Nov 2, 10:05 AM | 50 minutes ago |
| MACD: Sell Signal | Nov 2, 9:40 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 hour ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:40 AM | 4 days ago |
| RSI: Oversold | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 6 days ago |
News
1 day ago benzinga.com
Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week
Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
2 days ago benzinga.com
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses proprietary data and pattern recognition to highlight five stocks just under the surface that deserve attention.
2 days ago benzinga.com
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
The Stock Whisper Index is a market indicator highlighting stocks that are attracting heightened interest from traders and investors over the last trading week.
3 days ago benzinga.com
Natera, Shake Shack, eBay And More On CNBC's ‘Final Trades'
On CNBC's “Halftime Report Final Trades,” Rob Sechan, founder and managing partner of NewEdge Capital Group, picked eBay Inc. (NASDAQ:EBAY).
3 days ago benzinga.com
Natera, Shake Shack, eBay And More On CNBC’s ‘Final Trades’
CNBC Final Trades: Sechan picked eBay, Simpson Natera, Thomas COWZ ETF and Brown Shake Shack; all four gained Thursday.
3 days ago defenseworld.net
1,598 Shares of Natera, Inc. $NTRA Purchased by Bosman Wealth Management LLC
Bosman Wealth Management LLC acquired a new position in Natera, Inc. (NASDAQ: NTRA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
4 days ago zacks.com
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago seekingalpha.com
Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review
The portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology…
4 days ago seekingalpha.com
Alger Dynamic Opportunities Fund Q3 2026 Portfolio Update
Class A shares of the Alger Dynamic Opportunities Fund underperformed the S&P 500 Index during the third quarter of 2026. During the quarter, long positions, in aggregate, detracted from both…
5 days ago zacks.com
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?
Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.
5 days ago seekingalpha.com
Weatherbie Specialized Growth Fund Q3 2026 Portfolio Update
Natera reported stronger-than-expected results and raised its full-year outlook. Impinj reported stronger-than-expected results, including record revenue and profitability. Hamilton Lane shares…
-
5 days ago benzinga.com
BTIG Maintains Buy on Natera, Raises Price Target to $430
BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $320 to $430.
-
6 days ago benzinga.com
Natera Highlights New Signatera Genome Assay Data At ESMO 2026, With ctDNA Dynamics Predictive Of Survival Outcomes In Bladder Cancer
Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO OpenNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free…
6 days ago businesswire.com
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical…
6 days ago fool.com
Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?
FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
1 week ago businesswire.com
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of…
1 week ago fool.com
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.
Druckenmiller owns a large stake in Natera. The company is growing quickly by disrupting the healthcare testing market.
1 week ago 247wallst.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some…
1 week ago fool.com
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Both of these ETFs look the part, but only one is truly the better buy for investors.
1 week ago benzinga.com
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.81% on an annualized basis producing an average annual return of 28.94%. Currently, Natera has a market capitalization of…
1 week ago zacks.com
Natera Partners With TransCode to Advance Colorectal Cancer Trial
NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
-
2 weeks ago benzinga.com
Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $500
Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $375 to $500.
2 weeks ago defenseworld.net
2,138 Natera, Inc. $NTRA Shares Acquired by SteelPeak Wealth LLC
SteelPeak Wealth LLC grew its position in Natera, Inc. (NASDAQ: NTRA) by 81.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission…
2 weeks ago gurufocus.com
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology wi
2 weeks ago businesswire.com
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at…
2 weeks ago fxempire.com
Natera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms
Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.
2 weeks ago gurufocus.com
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease
-
2 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $435
Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $355 to $435.
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on Natera, Raises Price Target to $480
TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $340 to $480.
-
2 weeks ago benzinga.com
Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based…
3 weeks ago benzinga.com
Natera Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Natera (NASDAQ:NTRA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…
-
3 weeks ago benzinga.com
Natera Receives FDA's Breakthrough Device Designation For Its Multi-Cancer Early Detection Assay
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device…
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on Natera, Raises Price Target to $475
Barclays analyst Luke Sergott maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $340 to $475.
-
3 weeks ago benzinga.com
Citigroup Maintains Buy on Natera, Raises Price Target to $480
Citigroup analyst Albert Hu maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $365 to $480.
3 weeks ago benzinga.com
$1000 Invested In Natera 10 Years Ago Would Be Worth This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 29.68% on an annualized basis producing an average annual return of 43.44%. Currently, Natera has a market capitalization of…
-
4 weeks ago benzinga.com
Alliance Foundation Trials And Natera Launch AFT-70 NAVIGATE, Randomized Phase III Trial Evaluating MRD-Guided Treatment Strategy For Patients With Intermediate And High-Risk ER-Positive/HER2-Negative Early Breast Cancer
Trial will use Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s investigational oral SERD, aiming to spare…
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Natera, Raises Price Target to $475
Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $360 to $475.
1 month ago benzinga.com
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
1 month ago benzinga.com
$1000 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.64% on an annualized basis producing an average annual return of 29.65%. Currently, Natera has a market capitalization of…
1 month ago benzinga.com
Natera, UnitedHealth Group And A Tech Stock On CNBC’s ‘Final Trades’
CNBC’s Final Trades: Rob Sechan picks Hewlett Packard, Kevin Simpson favors Natera, and Stephen Weiss recommends UnitedHealth.
-
1 month ago benzinga.com
RBC Capital Maintains Outperform on Natera, Raises Price Target to $460
RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $350 to $460.
1 month ago benzinga.com
Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’
CNBC’s Final Trades featured Uber, Micron, Natera and Datadog, with analysts citing bullish views and all four stocks posting gains.
-
1 month ago benzinga.com
Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test
This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in…
-
1 month ago benzinga.com
UBS Maintains Buy on Natera, Raises Price Target to $435
UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $290 to $435.
-
1 month ago benzinga.com
Rothschild & Co Initiates Coverage On Natera with Buy Rating, Announces Price Target of $385
Rothschild & Co analyst Jamie Clark initiates coverage on Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $385.
-
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization of…
-
2 months ago benzinga.com
Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of…
-
2 months ago benzinga.com
Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells…
-
2 months ago benzinga.com
Here's How Much $1000 Invested In Natera 10 Years Ago Would Be Worth Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized basis producing an average annual return of 40.99%. Currently, Natera has a market capitalization of…
-
2 months ago benzinga.com
Citigroup Maintains Buy on Natera, Raises Price Target to $365
Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $315 to $365.